Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...
Hosted on MSN1mon
Sonnet BioTherapeutics begins trial combining SON-1010, trabectedinPRINCETON, NJ - Sonnet BioTherapeutics Holdings ... with a target enrollment of up to 18 patients. The primary outcome measures include safety, tolerability, pharmacokinetics, and pharmacodynamics ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback